Mirati, Aadi To Evaluate Adagrasib, Nab-sirolimus Combination To Treat NSCLC, Other Solid Tumors
(RTTNews) - Oncology company Mirati Therapeutics, Inc. (MRTX) and biopharmaceutical company Aadi Bioscience, Inc. (AADI) announced Wednesday a clinical collaboration to evaluate the combination of adagrasib, a KRASG12C selective inhibitor, and nab-sirolimus, a small molecule mTOR inhibitor complexed with human albumin in KRAS G12C mutant non-small cell lung cancer (NSCLC) and other solid tumors.
The primary objective of this multi-center, single-arm, open-label Phase 1/2 trial is to determine the optimal dose and recommended Phase 2 dose for the combination of adagrasib and nab-sirolimus in patients with KRASG12C - mutant solid tumors.
In addition, the study will investigate the safety, tolerability and efficacy of adagrasib and nab-sirolimus in combination in patients both with and without prior exposure to a KRASG12C inhibitor.
The trial will build on preclinical data showing enhanced anti-tumor efficacy with the combination of adagrasib and nab-sirolimus relative to either agent alone.
Under the terms of the collaboration agreement, Mirati will be responsible for sponsoring and operating the Phase 1/2 study, and jointly with Aadi, will oversee and share the cost of the study.
For More Such Health News, visit rttnews.com
TSX Pares Gains After Hitting Fresh Record High; Gildan Activewear Soars 11%
Swiss Market Ends On Firm Note
European Stocks Close Mostly Higher
Bay Street Likely To Open On Positive Note
U.S. Dollar Extends Fall Amid Fed Rate Cut Speculation
FTSE 100 Modestly Higher; Beazley Plunges Sharply
CAC 40 Up Nearly 0.5%; Essilor Rises Sharply
